Hellman Jordan Management Co. Inc. MA trimmed its holdings in Allergan PLC. (NYSE:AGN) by 23.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,308 shares of the company’s stock after selling 1,332 shares during the period. Allergan comprises about 1.9% of Hellman Jordan Management Co. Inc. MA’s holdings, making the stock its 13th largest position. Hellman Jordan Management Co. Inc. MA’s holdings in Allergan were worth $883,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Pathstone Family Office LLC lifted its stake in shares of Allergan by 3,327.3% in the second quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock valued at $2,035,000 after buying an additional 366 shares in the last quarter. Howard Hughes Medical Institute purchased a new stake in shares of Allergan in the second quarter valued at about $103,000. Massey Quick & Co. LLC raised its holdings in shares of Allergan by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after purchasing an additional 385 shares during the last quarter. Cable Hill Partners LLC raised its holdings in shares of Allergan by 255.2% in the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after purchasing an additional 370 shares during the last quarter. Finally, Pacific Center for Financial Services raised its holdings in shares of Allergan by 1.3% in the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock valued at $132,000 after purchasing an additional 7 shares during the last quarter. 81.34% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have recently commented on the stock. Wells Fargo & Company reiterated an “outperform” rating on shares of Allergan in a report on Monday, September 11th. Deutsche Bank reiterated a “buy” rating and issued a $262.00 target price on shares of Allergan in a report on Tuesday, September 12th. BidaskClub downgraded shares of Allergan from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Cantor Fitzgerald reiterated a “hold” rating on shares of Allergan in a report on Tuesday, August 29th. Finally, Cowen reiterated an “outperform” rating and issued a $400.00 target price on shares of Allergan in a report on Tuesday, August 29th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the stock. Allergan currently has a consensus rating of “Buy” and a consensus price target of $235.25.

In other Allergan news, insider William Meury sold 11,807 shares of Allergan stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher J. Coughlin bought 10,000 shares of the company’s stock in a transaction on Tuesday, December 5th. The shares were bought at an average price of $163.30 per share, with a total value of $1,633,000.00. The disclosure for this purchase can be found here. Insiders have acquired 17,630 shares of company stock valued at $2,890,057 in the last quarter. Company insiders own 0.36% of the company’s stock.

Shares of Allergan PLC. (NYSE AGN) opened at $170.94 on Friday. Allergan PLC. has a 1-year low of $160.07 and a 1-year high of $256.80. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. The stock has a market cap of $56,286.37, a PE ratio of 10.98, a P/E/G ratio of 1.13 and a beta of 1.11.

Allergan (NYSE:AGN) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.06 by $0.09. The business had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the company posted $3.32 earnings per share. analysts forecast that Allergan PLC. will post 16.27 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be given a dividend of $0.70 per share. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.64%. Allergan’s dividend payout ratio is presently -12.44%.

Allergan declared that its board has approved a stock repurchase program on Monday, September 25th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/12/15/allergan-plc-agn-shares-sold-by-hellman-jordan-management-co-inc-ma.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Stock Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related stocks with our FREE daily email newsletter.